We expect investors to focus on Compugen Ltd.’s (CGEN) progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteCompugen’s top line currently comprises revenues recognized from its license agreement with Gilead Sciences (GILD) and AstraZeneca. The company reported $6.7 million in revenues in the last reported quarter, comprising an upfro ...